Eye Cancer Stages: How Uveal Melanoma Staging Works
Staging is the process your care team uses to describe how big a tumor is and how far it has grown or spread. For most adults, "eye cancer" means uveal melanoma (also called intraocular melanoma or ocular melanoma), a cancer of the pigment cells in the middle layer of the eye. This guide focuses on how uveal melanoma is staged. It also explains staging for retinoblastoma, a different eye cancer that mainly affects young children and uses its own separate system.
Staging matters because it helps your doctor plan treatment, predict how the cancer is likely to behave, and decide how closely to watch you afterward. Unlike many cancers, uveal melanoma does not usually travel through the lymph nodes. It spreads through the bloodstream, most often to the liver, sometimes many years after the eye tumor was treated. Because of this, staging for uveal melanoma is based almost entirely on the tumor found in the eye itself, rather than on lymph node findings.
Stage is not the only piece of information that matters. Where the tumor sits in the eye (the choroid, the ciliary body, or the iris) affects both treatment choices and outlook. In recent years, doctors have added a third layer of information: tumor genetic testing. Looking at the tumor's chromosome 3 status and its gene expression profile helps estimate the chance that the cancer will spread later in life, and that estimate helps guide how often you will need follow-up liver scans and blood tests. Together, stage, tumor location, and tumor genetics give a fuller picture than stage alone.
If you were just diagnosed, it can help to first understand what eye cancer is and how eye cancer is diagnosed before reading about staging in detail. This guide walks through the TNM system doctors use for uveal melanoma, what each stage generally means for treatment, and how staging works differently for retinoblastoma.
How Doctors Stage Eye Cancer
Doctors use a system called TNM to stage uveal melanoma. TNM stands for tumor, node, and metastasis, and it was developed by the American Joint Committee on Cancer (AJCC). The T part describes the size of the tumor and how far it has grown within or beyond the eye. The N part describes whether the cancer has reached nearby lymph nodes (small, bean-shaped structures that are part of the immune system). The M part describes whether the cancer has spread to distant parts of the body.
The T category is based mainly on two measurements: how wide the tumor is across its base (the diameter) and how thick it is (the height, also called the apical height). These measurements are sorted into size groups that grew out of research from the Collaborative Ocular Melanoma Study (COMS), a large research program that studied uveal melanoma treatment and outcomes over many years. Beyond size, the T category also depends on which parts of the eye the tumor touches. A tumor that has grown into the ciliary body (the ring of muscle behind the iris that helps the eye focus) or has pushed outside the wall of the eye (extraocular extension) is placed in a higher, more advanced T category than a similarly sized tumor that has stayed within the choroid.
N describes regional lymph nodes. This is rare in uveal melanoma, because the middle layer of the eye has blood vessels but no lymphatic channels of its own. When lymph node spread does happen, it is usually only after a tumor has already grown through the outer wall of the eye and reached tissue with normal lymphatic drainage. Because node involvement is so uncommon, doctors do not routinely biopsy lymph nodes as part of staging the way they might for skin melanoma or breast cancer.
M describes metastasis, meaning spread to distant organs. Uveal melanoma metastasizes hematogenously, which means it travels through the bloodstream rather than the lymphatic system. The liver is by far the most common site, and doctors use blood tests that check liver function along with liver imaging, such as ultrasound or MRI, to look for it. This pattern is different from most cancers people are familiar with, and it is the reason liver monitoring becomes a lifelong habit for many people treated for uveal melanoma.
One detail worth knowing is that the AJCC staging rules are not identical for every part of the eye. Tumors of the iris (the colored part of the eye) are staged using their own T categories, but there is no complete stage grouping, meaning no official Stage I through Stage IV, specifically for iris melanoma. Ciliary body and choroidal melanomas, which make up the large majority of cases, do have a full stage grouping. Iris melanomas tend to be found earlier and generally carry a better outlook than tumors in the ciliary body or choroid.
Tumor genetic testing adds information that stage alone cannot capture. A tumor sample, usually taken through a biopsy or from tissue removed during treatment, can be tested for loss of one copy of chromosome 3 (sometimes called monosomy 3) and analyzed with a gene expression profile test, such as the validated 15-gene DecisionDx-UM test. These results sort tumors into lower-risk and higher-risk categories for future metastasis, which helps your doctor recommend how often you should have follow-up liver imaging. This is tumor testing, not a test of your own inherited genes, though a small share of uveal melanoma is linked to an inherited condition called BAP1 tumor predisposition syndrome. You can read more about this testing in the eye cancer diagnosis guide.
What Do the T, N, and M Categories Mean?
The categories below describe ciliary body and choroidal melanoma, which is the most common form of uveal melanoma and the only site with a full AJCC stage grouping. Each T category also has lettered subgroups (for example, T1a or T2b) that account for ciliary body involvement and extraocular extension, but the general pattern below covers the main logic.
T1: The tumor is in the smallest size group. It has not grown into the ciliary body or outside the eyeball.
T2: The tumor is in the next size group up from T1. Growth into the ciliary body or a small amount of extraocular extension moves a tumor into a higher lettered subgroup within this category.
T3: The tumor is in a larger size group than T2, again with subgroups depending on ciliary body involvement or extraocular extension.
T4: The tumor is in the largest size group, or it has extraocular extension larger than 5 millimeters (about one fifth of an inch) across, regardless of the tumor's size within the eye.
N0: The cancer has not spread to nearby lymph nodes.
N1: The cancer has spread to nearby lymph nodes, or small deposits of cancer cells are found in other parts of the eye separate from the main tumor.
M0: No spread to distant organs has been found.
M1a: The cancer has spread to a distant site, and the largest area of spread measures no more than about 3 centimeters (a little over an inch) across.
M1b: The largest area of spread measures between about 3 and 8 centimeters across.
M1c: The largest area of spread measures more than about 8 centimeters across.
Iris melanoma uses a different, simpler T scale of its own, generally based on how much of the iris the tumor covers and whether it has grown into the ciliary body, choroid, or outside the eye. The N and M categories are the same across all three tumor locations. Your pathology report and staging summary will spell out your exact category, and your doctor can walk through what each letter and number means for your specific tumor.
The Stages of Eye Cancer
Once the T, N, and M categories are known, they are combined into an overall stage, written as Stage I through Stage IV. Some stages are further divided into sub-stages, such as Stage IIA and Stage IIB, to capture finer differences in tumor size and spread.
Stage I
Stage I means the tumor is small and confined to the choroid, with no ciliary body involvement, no extraocular extension, and no spread to lymph nodes or distant organs. This is the earliest and most favorable stage. Treatment often focuses on eye-sparing options, such as plaque brachytherapy (a small radioactive disc placed temporarily on the eye) or other forms of radiation, since small tumors can frequently be treated without removing the eye.
Stage II
Stage II tumors are larger than Stage I tumors, or they involve the ciliary body, but they still have not spread beyond the eye or to lymph nodes. This stage is divided into Stage IIA and Stage IIB based on the exact size and extent of ciliary body involvement. Radiation therapy, including plaque brachytherapy or proton beam therapy, remains a common eye-sparing option at this stage, though the choice depends on tumor size, location, and how much healthy vision might be affected.
Stage III
Stage III includes larger tumors, tumors with more extensive ciliary body involvement, or tumors with a modest amount of extraocular extension, again without lymph node or distant spread. This stage is divided into Stage IIIA, Stage IIIB, and Stage IIIC. Treatment decisions become more individualized here. Some tumors can still be treated with radiation, while others, especially very large tumors or those that have caused significant vision loss or eye pain, may be better treated with enucleation (surgical removal of the eye). Your surgical oncology team will weigh the chances of controlling the tumor against the chances of saving useful vision.
Stage IV
Stage IV means the cancer has spread to nearby lymph nodes or to distant parts of the body, most often the liver, regardless of the size of the tumor in the eye. This stage calls for treatment aimed at both the eye tumor and the area of spread, and your care team may include a liver specialist or medical oncologist alongside your eye cancer doctors. For a subset of people with metastatic uveal melanoma who carry a specific tissue type called HLA-A*02:01, an immunotherapy called tebentafusp is an approved treatment option; whether it applies to you depends on tissue typing that your oncologist can arrange. Clinical trials are another option worth discussing at this stage, and you can learn more in the guide to joining a clinical trial for eye cancer.
Staging for Retinoblastoma
Retinoblastoma is a different eye cancer that mainly affects young children, usually before age 5, and it works differently from uveal melanoma in almost every way, including how it is staged. Retinoblastoma starts in the retina (the light-sensing layer at the back of the eye) and is linked to changes in the RB1 gene. Because it is a completely separate disease, it uses its own staging systems rather than the TNM system described above.
The system most doctors use for retinoblastoma that is still confined to the eye is called the International Intraocular Retinoblastoma Classification. It sorts tumors into five groups, labeled A through E, based on tumor size, location, and how much the cancer has spread within the eye itself.
Group A: Small tumors, no more than 3 millimeters across, that are confined to the retina and are away from important structures such as the optic disc and the foveola (the center of vision).
Group B: All other tumors that are still confined to the retina but are either larger than Group A tumors or closer to the optic disc or foveola.
Group C: Tumors with a small, well-defined amount of spread into the fluid inside the eye (vitreous seeding) or under the retina (subretinal seeding), close to the main tumor.
Group D: Larger or less well-defined tumors with more widespread seeding, sometimes with the retina partly detached from the back of the eye.
Group E: Tumors that are very large or advanced, for example bleeding into the eye, causing high pressure inside the eye (glaucoma), or growing into the optic nerve, which leaves little chance of saving the eye.
Treatment approach depends heavily on whether the tumor is confined to the eye and which group it falls into. Group A and many Group B tumors are often treated with eye-sparing approaches such as chemotherapy (given systemically or delivered directly to the eye's blood supply), laser treatment, or cryotherapy (freezing). Group D and Group E tumors are more likely to need enucleation, though newer treatment approaches mean that even some advanced eyes have a chance of being saved today. For cancer that has spread beyond the eye, doctors may also use the International Retinoblastoma Staging System, which describes stages 0 through IV based on factors such as whether the eye was removed and whether cancer has reached the area around the eye, nearby lymph nodes, or distant sites such as the brain or bone marrow.
The most important thing for parents to know is that survival outcomes for retinoblastoma are generally excellent with prompt treatment, even when a tumor falls into a more advanced group, especially in countries with good access to specialized eye cancer care. What becomes harder as the group advances is not usually survival, but saving the eye itself and preserving useful vision in that eye. If your child has been diagnosed, your care team can explain exactly what group applies and what that means for the treatment plan and the chances of saving the eye. Genetic counseling and testing for the RB1 gene, for your child and sometimes the whole family, is also a standard and valuable part of care, since retinoblastoma can be hereditary.
Recurrent and Metastatic Eye Cancer
For uveal melanoma, recurrence usually means the tumor comes back in or near the eye after initial treatment, while metastasis means the cancer has spread to another part of the body, most often the liver. These are not the same thing, and either can happen on its own. A tumor can be fully controlled in the eye while cells that had already entered the bloodstream before treatment go on to grow elsewhere years later.
One of the most distinctive features of uveal melanoma is how late metastasis can appear. Unlike many cancers, where recurrence risk drops sharply after the first few years, uveal melanoma can spread to the liver a decade or more after the original eye tumor was successfully treated. Research from the Collaborative Ocular Melanoma Study found that the liver was the only detectable site of metastasis in roughly half of patients who developed spread, with the rest showing metastasis in the liver along with other organs such as the lungs or bones. Over the long term, up to about half of people treated for uveal melanoma eventually develop metastatic disease, though your individual risk depends heavily on your tumor's size, location, and genetic profile.
Because of this late and liver-focused pattern, lifelong follow-up imaging is a real, ongoing part of care rather than something that ends after a set number of years. Most people who have been treated for uveal melanoma have periodic liver imaging, such as ultrasound or MRI, along with liver function blood tests, often continuing indefinitely. Your doctor will use your tumor's stage, location, and genetic testing results, including chromosome 3 status and gene expression profile, to decide how often you need these checks.
If metastasis is found, treatment shifts from managing the eye tumor to managing disease elsewhere in the body, and your care team will likely expand to include medical oncology and, if the liver is involved, a liver specialist. Options can include liver-directed treatments, systemic therapy, and for eligible patients, the targeted immunotherapy tebentafusp or a clinical trial. This is a different situation from local recurrence in the eye, which is managed by your eye cancer team and may still allow the eye to be saved in some cases. Speak with your own care team about which follow-up schedule and treatment options fit your specific situation.
What Your Stage Does and Does Not Tell You
Your stage is a genuinely useful tool. It guides which treatments are reasonable to consider, helps your care team set a follow-up schedule, and gives a general sense of what to expect on average for people with a similar tumor. It is a summary built from measurements and findings that were true on the day of diagnosis.
What stage cannot do is predict your own individual outcome. Two people with the exact same stage can have different outcomes, because stage does not capture every biological detail of a tumor. This is exactly why tumor genetic testing has become such an important addition. Chromosome 3 status and gene expression profile testing look directly at the tumor's biology and add real prognostic information beyond stage alone, helping refine your personal risk estimate and tailor how closely you are watched afterward.
It also helps to remember that statistics describe groups of people, not individuals. Survival numbers reported for a given stage are averages across many patients treated at different times, with different tumor genetics, ages, and overall health. Your own outlook depends on all of these factors together, not on stage in isolation. For a fuller picture of how outcomes are reported and what they do and do not mean for you personally, see the eye cancer survival rates guide.
Finally, staging and genetic testing results are meant to support a conversation with your doctor, not replace one. Only your own care team, who knows your full medical history, exam findings, and test results, can help you understand what your particular stage and genetic profile mean for your treatment options and outlook. For a broader look at what treatment might involve at each stage, visit the eye cancer treatment guide, and consider bringing the questions to ask about eye cancer guide with you to your next appointment.